Clinical Trials Directory

Trials / Unknown

UnknownNCT05687422

Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy

A Randomized Controlled Study of Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Beijing Hospital · Other Government
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Not accepted

Summary

Central serous chorioretinopathy (CSC) is a common eye disease mainly involving the macular area, causing central visual acuity loss. Recently, subthreshold micropulse laser used in treating chronic CSC is proved to be safe and effective. However, some studies indicate that it's less effective than half dose photodynamic therapy (PDT). Certain physicians, including us, think that this may be related to micropulse laser parameters. Thus we need to explore better laser patterns to replace PDT in treating chronic CSC. The aim of this study is to compare the treatment effect of two different patterns of laser parameters (small and regular spot diameter) in treating chronic CSC. In this randomized, double blinded, controlled trial, by comparing the subretinal fluid regression ratio, central retinal thickness, macular microvisual field, macular vascular density, chroidal volume changes and visual acuity of two groups 6 months after micropulse laser treatment, we aim to evaluate the safety and efficacy of refined micropulse laser in treating chronic CSC.

Conditions

Interventions

TypeNameDescription
PROCEDURE100μm laser spot diameter micropulse laser100μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
PROCEDURE200μm laser spot diameter micropulse laser200μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months

Timeline

Start date
2023-02-01
Primary completion
2023-12-31
Completion
2023-12-31
First posted
2023-01-18
Last updated
2023-01-18

Source: ClinicalTrials.gov record NCT05687422. Inclusion in this directory is not an endorsement.